Bikash Medhi to Antiviral Agents
This is a "connection" page, showing publications Bikash Medhi has written about Antiviral Agents.
Connection Strength
0.878
-
Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review. Eur J Pharmacol. 2021 Sep 05; 906:174233.
Score: 0.088
-
Clinically relevant cell culture models and their significance in isolation, pathogenesis, vaccine development, repurposing and screening of new drugs for SARS-CoV-2: a systematic review. Tissue Cell. 2021 Jun; 70:101497.
Score: 0.085
-
Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacol Rep. 2021 Jun; 73(3):736-749.
Score: 0.085
-
Indian contribution toward biomedical research and development in COVID-19: A systematic review. Indian J Pharmacol. 2021 Jan-Feb; 53(1):63-72.
Score: 0.085
-
Regulatory approval for COVID-19 across the globe. Indian J Pharmacol. 2020 Nov-Dec; 52(6):457-466.
Score: 0.084
-
Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients. Indian J Pharmacol. 2020 Sep-Oct; 52(5):414-421.
Score: 0.083
-
Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2. J Mol Graph Model. 2020 12; 101:107716.
Score: 0.083
-
Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis. Indian J Pharmacol. 2020 Jul-Aug; 52(4):313-323.
Score: 0.082
-
Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. J Med Virol. 2020 07; 92(7):776-785.
Score: 0.081
-
Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach. Indian J Pharmacol. 2020 Jan-Feb; 52(1):1-5.
Score: 0.080
-
Novel therapeutic approaches toward Hantaan virus and its clinical features' similarity with COVID-19. Indian J Pharmacol. 2020 Sep-Oct; 52(5):347-355.
Score: 0.021
-
Update on the target structures of SARS-CoV-2: A systematic review. Indian J Pharmacol. 2020 Mar-Apr; 52(2):142-149.
Score: 0.020